Skip to content
Screener

Anika Therapeutics ANIK Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$27.8MBeat by $17.0K
EPS$0.04Beat by $0.02
Revenue estimate$27.8M
EPS estimate$0.02

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$29.7M
EPS estimate$0.17

Financials

Q3 2025

Income statement

See full
Revenue$27.8M-28.2%
Net income-$2.3M+92.2%

Balance sheet

See full
Cash & equivalents$58.0M-7.0%
Total debt$24.5M-11.0%
Total equity$146.8M-18.4%
Total assets$189.4M-18.1%

Cash flow

See full
Operating cash flow$6.9M+37.0%
CapEx$1.9M+55.2%
Free cash flow$5.0M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$135.53M-62.9%
Enterprise value$102.05M-69.1%
P/S1.6×-0.6×

Profitability

See full
Net margin-40.2%-9.8pp

Returns & leverage

See full
Return on equity-20.2%-7.0pp
Debt / equity0.2×0.0×
Current ratio5.3×0.0×

Segments

By geography

See full
Europe$5.7M-0.4%
Other Location$4.7M-12.4%

By product

See full
OEM Channel$15.8M—
Commercial Channel$12.0M—

FAQ

When did Anika Therapeutics report Q3 2025 earnings?
Anika Therapeutics (ANIK) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Anika Therapeutics's Q3 2025 revenue and EPS?
Anika Therapeutics reported revenue of $27.8M and eps of $0.04 for Q3 2025.
Did Anika Therapeutics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $27.8M by $17.0K. EPS beat the consensus estimate of $0.02 by $0.02.
How did Anika Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 28.2% from $38.8M a year earlier.
Where can I find Anika Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-007003) and the 10-Q periodic report (0001171843-25-007032) directly on SEC EDGAR. The filing index links above go to sec.gov.